Docusign Envelope ID: 317E4867-DC75-4156-971F-0B217E0B5C27

GENERALFORSAMLINGSPROTOKOLLAT

DANISH BIO - DANSK BIOTEK

MINUTES OF ANNUAL GENERAL MEETING

DANISH BIO - DANSK BIOTEK

Docusign Envelope ID: 317E4867-DC75-4156-971F-0B217E0B5C27

GENERALFORSAMLINGSPROTOKOLLAT

ORDINÆR GENERALFORSAMLING

DATO: 27. MAJ 2025

DANISH BIO - DANSK BIOTEK

CVR-NR. 28 43 65 72

Dags dato afholdtes ordinær generalforsamling i DANISH BIO - DANSK BIOTEK, CVR-nr. 28 43 65 72 ("**Foreningen**"), på adressen Tietgens Hus, Børsgade 4, 1215 København K.

Dagsordenen var som følger:

a) Valg af dirigent

b) Formandens beretning

c) Godkendelse af regnskab for 2024

d) Valg af formand

e) Valg af medlemmer til bestyrelsen

f) Valg af revisor

g) Fastsættelse af kontingent for 2026

h) Behandling af forslag

i) Eventuelt

Ad a)

Til dirigent valgtes advokat Thomas Holst Laursen, Plesner Advokatpartnerselskab, der konstaterede, at generalforsamlingen var lovligt indkaldt og beslutningsdygtig i forhold til punkterne på dagsordenen.

Ad b)

Bestyrelsesformand Hans Schambye aflagde sin beretning om Foreningens aktiviteter i det forgangne regnskabsår.

Generalforsamlingen tog formandens beretning til efterretning.

MINUTES OF ANNUAL GENERAL MEETING

ANNUAL GENERAL MEETING

DATE: 27 MAY 2025

DANISH BIO - DANSK BIOTEK

CVR NO. 28 43 65 72

Today the Annual General Meeting of DANISH BIO - DANSK BIOTEK, CVR no. 28 43 65 72 (the "**Association**"), was held at Tietgens Hus, Børsgade 4, DK-1215 Copenhagen.

The agenda was as follows:

a) Election of Chairman of the Annual General Meeting

b) Chairman's statement

c) Approval of financial result for 2024

d) Election of Chairman

e) Election of Members of the Board

f) Election of Auditor

g) Determination of membership fees for 2026

h) Discussion of proposals

i) Any other business

Re a)

Attorney-at-law, Thomas Holst Laursen, Plesner Advokatpartnerselskab, was elected Chairman of the general meeting. The Chairman of the general meeting ascertained that the general meeting was legally convened and constituted a quorum in relation to the items on the agenda.

Re b)

The Chairman of the Board, Hans Schambye, gave his statement on the activities of the Association during the past accounting year.

The general meeting adopted the Chairman of the Board's statement.

Docusign Envelope ID: 317E4867-DC75-4156-971F-0B217E0B5C27

Ad c)

Årsregnskab med revisionspåtegning for 2024 blev fremlagt til generalforsamlingens godkendelse.

Foreningens årsrapport blev enstemmigt og med alle stemmer godkendt af generalforsamlingen.

Re c)

The annual report with the auditor's report for 2024 was presented for the general meeting's approval.

The annual report for the Association was unanimously and with all votes approved by the general meeting.

Ad d)

Det blev oplyst, at bestyrelsesformanden vælges for en toårig periode og kan genvælges.

Der forelå forslag om genvalg af Hans Schambye som formand (2025-2027).

Forslaget blev enstemmigt og med alle stemmer vedtaget af generalforsamlingen.

Re d)

It was informed that the Chairman of the Board is elected for a two-year period and may be re-elected.

A proposal was submitted to re-elect Hans Schambye as Chairman of the Board (2025-2027).

The proposal was unanimously and with all votes approved by the general meeting.

Ad e)

Det blev oplyst, at bestyrelsen vælges for en toårig periode og kan genvælges.

Thomas Kongstad Petersen, Jørgen Godt Olsen og Mai-Britt Zocca fortsætter som bestyrelsesmedlemmer i henhold til deres eksisterende valgperioder (2024-2026).

Der forelå forslag om genvalg af Hans Schambye, Henrik Blou, Lone Dybdal Nilsson og Søren Møller som bestyrelsesmedlemmer.

Der forelå desuden forslag om at vælge Lasse Nørregaard som nyt medlem af bestyrelsen (tidligere bestyrelsesobservatør).

Forslaget blev enstemmigt og med alle stemmer vedtaget af generalforsamlingen.

Bestyrelsen består herefter af følgende medlemmer:

- Hans Schambye, CEO, Galecto Inc. (Formand) (2025-2027)
- Lasse Nørregaard, Chief Business Officer, XY Therapeutics, Loma Therapeutics, Probmet Therapeutics (2025-2027)
- Henrik Blou, CEO, Gubra (2025-2027)
- Lone Dybdal Nilsson, Vice President, Applied Research Agriculture & Industrial Biosolutions, Novozymes North America Inc. (2025-2027)
- Søren Møller, Managing Partner, Novo Holdings A/S (2025-2027)
- Thomas Kongstad Petersen, Chief Operating Officer, NMD Pharma (2024-2026)

Re e)

It was informed that the Board is elected for a two-year period and may be re-elected.

Thomas Kongstad Petersen, Jørgen Godt Olsen and Mai-Britt Zocca will continue as members of the Board in accordance with their current election periods (2024-2026).

A proposal was submitted to re-elect Hans Schambye, Henrik Blou, Lone Dybdal Nilsson and Søren Møller as members of the Board.

Further, a proposal was submitted to elect Lasse Nørregaard as a new member of the Board (former board observer).

The proposal was unanimously and with all votes approved by the general meeting.

Accordingly, the members of the Board are the following:

- Hans Schambye, CEO, Galecto Inc. (Chairman) (2025-2027)
- Lasse Nørregaard, Chief Business Officer, XY Therapeutics, Loma Therapeutics, Probmet Therapeutics (2025-2027)
- Henrik Blou, CEO, Gubra (2025-2027)
- Lone Dybdal Nilsson, Vice President, Applied Research Agriculture & Industrial Biosolutions, Novozymes North America Inc. (2025-2027)
- Søren Møller, Managing Partner, Novo Holdings A/S (2025-2027)
- Thomas Kongstad Petersen, Chief Operating Officer, NMD Pharma (2024-2026)

Docusign Envelope ID: 317E4867-DC75-4156-971F-0B217E0B5C27

- Mai-Britt Zocca, CEO & founder, IO Biotech ApS (2024-2026)
- Jørgen Godt Olsen, Executive Vice President, Niels Clauson-Kaas (2024-2026)

Ad f)

Der forelå forslag om genvalg af EY Godkendt Revisionspartnerselskab, CVR-nr. 30 70 02 28, som Foreningens revisor.

Forslaget blev enstemmigt og med alle stemmer vedtaget af generalforsamlingen.

Ad g)

Der forelå forslag om, at kontingent for 2026 skulle fastsættes uændret i forhold til 2025.

Forslaget blev enstemmigt og med alle stemmer vedtaget af generalforsamlingen.

I overensstemmelse hermed fastsattes kontingentet for 2026 som følger:

Start-ups

- Biotek start-ups (indtil kapital på 10 mio. DKK er rejst): GRATIS

Offentlige interessemedlemmer og små virksomhedsmedlemmer

- DKK 5.000

Lægemiddel & industriel biotek/Pharma + investorer

- Mindre end 10 ansatte: DKK 5.000
- Mellem 10-200 ansatte: DKK 15.000
- Mere end 200 ansatte: DKK 35.000
- Mere end 1,000 ansatte: DKK 50.000

Associerede medlemmer

- Mindre end 10 ansatte: DKK 15.000
- Mellem 10-200 ansatte: DKK 20.000
- Mere end 200 ansatte: DKK 40.000

Medlemmer med udenlandsk hjemsted

- Halv pris på medlemskontingentet for den relevante medlemskategori

Ad h)

Der forelå ingen indkomne forslag.

- Mai-Britt Zocca, CEO & founder, IO Biotech ApS (2024-2026)
- Jørgen Godt Olsen, Executive Vice President, Niels Clauson-Kaas (2024-2026)

Re f)

A proposal to re-elect EY Revisionspartnerselskab, CVR no. 30 70 02 28, as the Association's auditor was submitted.

The proposal was unanimously and with all votes approved by the general meeting.

Re g)

A proposal was submitted that the membership fees for 2026 should remain unchanged compared to 2025.

The proposal as was unanimously and with all votes approved by the general meeting.

Accordingly, the membership fees for 2026 were determined as follows:

Start-ups

- Biotech start-ups (until DKK 10 million in capital has been raised): FREE

Public members and small entity members

- DKK 5,000

Medical & Industrial Biotech/Pharma + Investors

- Less than 10 employees: DKK 5,000
- Between 10-200 employees: DKK 15,000
- More than 200 employees: DKK 35,000
- More than 1,000 employees: DKK 50,000

Associated members

- Less than 10 employees:: DKK 15,000
- Between 10-200 employees: DKK 20,000
- More than 200 employees: DKK 40,000

Members with foreign domicile

- Half price of membership fee for the relevant membership category

Re h)

No proposals were received for discussion.

Docusign Envelope ID: 317E4867-DC75-4156-971F-0B217E0B5C27

Ad i)

Et medlem af Foreningen gjorde opmærksom på en række aktuelle forhold, som bør indarbejdes i Foreningens arbejde. Dette omfatter blandt andet krav til governance samt lovgivningsmæssige krav, herunder i skattemæssig henseende, som har særlig relevans for start ups. Bestyrelsen blev på den baggrund opfordret til fortsat at have fokus på disse forhold i sit arbejde.

Bestyrelsesformanden kvitterede for bemærkningerne og tilkendegav, at dette arbejde er centralt for Foreningen. Videre bemærkede bestyrelsesformanden, at Foreningen aktuelt deltager i samarbejder om to sæt analyser af henholdsvis den danske og den europæiske biotekbranche.

Der var ingen yderligere bemærkninger under dette punkt.

- 0 -

Generalforsamling hævet.

Re i)

A member of the Association pointed out a number of current matters that could be considered for incorporation into the Association's work. These include, among other things, requirements relating to governance as well as legislative requirements, including in respect of taxation, which are of particular relevance to start-ups. On that basis, the Board of Directors was encouraged to maintain its focus on these matters in its ongoing work.

The Chairman of the Board acknowledged the comments and noted that this work is central to the Association. The Chairman of the Board further noted that the Association is currently engaged in collaborations concerning two sets of analyses of the Danish and European biotech sectors, respectively.

There were no further comments under this item.

- 0 -

The general meeting adjourned.

Som dirigent / As Chairman of the Annual General Meeting:

Signed by:
24BEEB6032DF4EC...

Thomas Holst Laursen